SCHEMBL2294947

SCHEMBL2294947

COc1ccc(Nc2nc(-c3cc(O)c(O)c(O)c3)nc3ccccc23)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 11/20 0.76
MEN1 O00255 9/20 0.74
KMT2A Q03164 9/20 0.74
ATM Q13315 1/20 0.71
ABCC1 P33527 2/20 0.69
NPC1 O15118 1/20 0.66
ABCB1 P08183 3/20 0.65
KDM1A O60341 1/20 0.65
MAPT P10636 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
GAA P10253 2/20 0.61
KDM4E B2RXH2 2/20 0.60
LMNA P02545 2/20 0.60
ALDH1A1 P00352 1/20 0.60
GBA1 P04062 1/20 0.60
HTT P42858 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
PDE5A O76074 1/20 0.60
TP53 P04637 1/20 0.59
CYP1A2 P05177 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16404472 0.90 ABCG2 (0.87) ABCG2MEN1KMT2AATMABCC1
SCHEMBL2296338 0.88 ABCG2 (0.70) ABCG2MEN1KMT2AABCC1MAPT
SCHEMBL2296472 0.87 ABCG2 (0.74) ABCG2MEN1KMT2AABCC1ABCB1
SCHEMBL2294276 0.87 ABCG2 (0.78) ABCG2MEN1KMT2AABCC1KDM1A
SCHEMBL1064726 0.86 ABCG2 (1.00) ABCG2MEN1KMT2AATMABCC1
SCHEMBL16404494 0.86 ABCG2 (0.95) ABCG2MEN1KMT2AATMABCC1
SCHEMBL2231290 0.85 ABCG2 (0.55) ABCG2MEN1KMT2AATMABCC1
SCHEMBL16404317 0.85 MEN1 (0.84) ABCG2MEN1KMT2AATMABCC1
SCHEMBL2299801 0.84 ABCG2 (0.74) ABCG2MEN1KMT2AABCC1MAPT
SCHEMBL16404339 0.84 ABCG2 (0.72) ABCG2MEN1KMT2AATMABCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528606-B1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS LEVITZKI ALEXANDER (IL) 2014-09-24 EP disclosed
US-8759363-B2 Quinazoline-based T cell proliferation inhibitors YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2014-06-24 US disclosed
US-20130109706-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSALEM LTD. (IL) 2013-05-02 US disclosed
EP-2528606-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2012-12-05 EP disclosed
WO-2011092695-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109706-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS IL2, CD4, NFATC1 ABCG2 2405/4885MEN1 3730/4885KMT2A 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.